PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
- Conditions
- Malignant MelanomaMelanomaMetastatic MelanomaSolid Tumors
- Interventions
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 185
- Registration Number
- NCT06799533
- Locations
- 🇺🇸
The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only), Santa Monica, California, United States
🇺🇸Presbyterian/St. Luke's Medical Center, Denver, Colorado, United States
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06790420
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
- Conditions
- Community-Acquired Pneumonia (CAP)
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22234435
- Registration Number
- NCT06782282
- Locations
- 🇺🇸
Pfizer United States, New York, New York, United States
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1020
- Registration Number
- NCT06760637
- Locations
- 🇧🇬
Complex Oncology Center - Shumen, Shumen, Bulgaria
🇺🇸Ironwood Cancer & Research Centers, Scottsdale, Arizona, United States
🇺🇸Highlands Oncology, Rogers, Arkansas, United States
A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
- Conditions
- Pneumococcal ImmunizationSafety
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 660
- Registration Number
- NCT06760208
- Locations
- 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Conditions
- Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 714
- Registration Number
- NCT06758401
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸BRCR Global, Plantation, Florida, United States
🇺🇸Hope and Healing Cancer Services, New Lenox, Illinois, United States
Secondary Databased Post-marketing Surveillance Study of BNT162b2
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06743334
- Locations
- 🇰🇷
Pfizer, Soeul, Korea, Republic of
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT06735742
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
- Conditions
- Prostate Cancer
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 104
- Registration Number
- NCT06733337
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 252
- Registration Number
- NCT06717425
- Locations
- 🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Westside Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸New Horizon Research Center, Miami, Florida, United States